Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Corinne Frere; Soraya Mezouar; Léa Plantureux; Lydie Crescence; Laurence Panicot-Dubois; Christophe Dubois

doi:10.1016/S0049-3848(16)30167-0

Journal articles

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Corinne Frere ^{1, 2} Soraya Mezouar ^{1, 2} Léa Plantureux ^{1, 2} Lydie Crescence ^{1, 2} Laurence Panicot-Dubois ^{1, 2} Christophe Dubois ^{1, 2}

1 VRCM - Vascular research center of Marseille

2 Physiopathologie de l'Endothelium

VRCM - Vascular research center of Marseille

Abstract : In clinical studies, thromboprophylaxis with low-molecular-weight heparins (LMWHs) has been demonstrated to reduce the risk of venous thromboembolism and to improve outcomes in cancer patients. Moreover, preclinical models have previously suggested that LMWHs may also offer additional benefits through direct antitumor properties. However, the optimal doses of LMWHs that may prevent both cancer-related thrombosis and tumor development are yet unknown.

Document type :

Journal articles

Domain :

Life Sciences [q-bio]

Complete list of metadata

https://hal-amu.archives-ouvertes.fr/hal-01451070
Contributor : Françoise Dignat-George Connect in order to contact the contributor
Submitted on : Tuesday, January 31, 2017 - 4:01:17 PM
Last modification on : Wednesday, November 3, 2021 - 9:52:35 AM

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Identifiers

Collections

Citation

Export

Metrics

92

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Identifiers

Collections

Citation

Export

Share

Metrics

92